Similar articles

• A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

  Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico). Ojea A, et al. Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27. Eur Urol. 2007. PMID: 17485161 Clinical Trial.
• Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.

  Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y. Uchida A, et al. Urology. 2007 Feb;69(2):275-9. doi: 10.1016/j.urology.2006.10.017. Urology. 2007. PMID: 17320663
• Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.

  Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y; BCG Tokyo 172 Strain Study Group. Hinotsu S, et al. Urology. 2006 Mar;67(3):545-9. doi: 10.1016/j.urology.2005.09.045. Urology. 2006. PMID: 16527576 Clinical Trial.
• Intravesical mitomycin C for superficial transitional cell carcinoma.

  Bolenz C, Cao Y, Arancibia MF, Trojan L, Alken P, Michel MS. Bolenz C, et al. Expert Rev Anticancer Ther. 2006 Aug;6(8):1273-82. doi: 10.1586/14737140.6.8.1273. Expert Rev Anticancer Ther. 2006. PMID: 16925493 Review.
• [Bacillus of Calmette-Guérin immunotherapy: which protocol?].

  Saint F. Saint F. Prog Urol. 2008 May;18 Suppl 5:S99-104. doi: 10.1016/S1166-7087(08)72485-0. Prog Urol. 2008. PMID: 18585635 Review. French.